GRI Bio Inc

Company Profile

gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri’s natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri’s lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.